Abstract

Extraskeletal Ewing sarcoma (EES)/primitive neuroectodermal tumours (PNET) are rare soft tissue sarcomas. Prognostic factors and optimal therapy are still unconfirmed. We performed a retrospective analysis on patients to explore the clinic characteristics and prognostic factors of this rare disease. A total of 37 patients older than 15 years referred to our institute from Jan., 2002 to Jan., 2012 were reviewed. The characteristics, treatment and outcome were collected and analyzed. The median age was 28 years (range 15-65); the median size of primary tumours was 8.2 cm (range 2-19). Sixteen patients (43%) had metastatic disease at the initial presentation. Wide surgical margins were achieved in 14 cases (38%). Anthracycline or platinum-based chemotherapy was performed on 29 patients (74%). Radiotherapy was delivered in 13 (35%). At a median follow-up visit of 24 months (range 2-81), the media event-free survival (EFS) and overall survival (OS) were 15.8 and 30.2 months, respectively. The 3-year EFS and OS rates were 24% and 43%, respectively. Metastases at presentation and wide surgical margins were significantly associated with OS and EFS. Tumour size was significantly associated with OS but not EFS. There were no significant differences between anthracycline and platinum based chemotherapy regarding EFS and OS. EES/PNET is a malignant tumour with high recurrence and frequent distant metastasis. Multimodality therapy featuring wide surgical margins, aggressive chemotherapy and adjuvant local radiotherapy is necessary for this rare disease. Platinum-based chemotherapy can be used as an adjuvant therapy.

Highlights

  • IntroductionThe Ewing sarcoma family of tumours (ESFT) consists of a group of tumours including classic Ewing sarcoma of bone, Askin tumours of the chest wall, Extraskeletal Ewing sarcoma (EES) and primitive neuroectodermal tumours of bone or soft tissues (Maheshwari et al, 2010)

  • Metastases at presentation and wide surgical margins were significantly associated with overall survival (OS) and event-free survival (EFS)

  • The Ewing sarcoma family of tumours (ESFT) consists of a group of tumours including classic Ewing sarcoma of bone, Askin tumours of the chest wall, Extraskeletal Ewing sarcoma (EES) and primitive neuroectodermal tumours of bone or soft tissues (Maheshwari et al, 2010)

Read more

Summary

Introduction

The Ewing sarcoma family of tumours (ESFT) consists of a group of tumours including classic Ewing sarcoma of bone, Askin tumours of the chest wall, Extraskeletal Ewing sarcoma (EES) and primitive neuroectodermal tumours of bone or soft tissues (Maheshwari et al, 2010). Rare, such tumours constitute the second most frequent sarcoma of bone in child and adolescents (Herzog, 2005). Metastases at presentation and wide surgical margins were significantly associated with OS and EFS. Multimodality therapy featuring wide surgical margins, aggressive chemotherapy and adjuvant local radiotherapy is necessary for this rare disease. Platinum-based chemotherapy can be used as an adjuvant therapy

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call